cemacabtagene ansegedleucel vs Tafasitamab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Large B-Cell Lymphoma

Shared mechanism: CD19 · full Large B-Cell Lymphoma pipeline

cemacabtagene ansegedleucel

Developed by Allogene Therapeutics, Inc.

Phase 2 in Large B-Cell Lymphomacell therapy
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT06500273 (registry estimate)

No aligned efficacy figure on record for this race.

Tafasitamab

Marketed by Incyte and partners

Approved in Large B-Cell Lymphomamonoclonal antibody
Weak signal

NCT02399085 · Phase 2 · completed

The study was open-label and treated participants in a single group without randomization or a comparator. Its primary endpoint was an objective tumor response measure, with 46 of 80 treated with both drugs achieving a complete or partial response, but the uncontrolled design limits how confidently this result can be attributed to tafasitamab.

Next expected readout: January 2027 · NCT06760156 (registry estimate)

Reported efficacy

Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants (not_applicable)

Result source: NCT02399085

Results for Large B-Cell Lymphoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

cemacabtagene ansegedleucel: no structured comparison results are available for Large B-Cell Lymphoma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Tafasitamab
Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants NCT02399085 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cemacabtagene ansegedleucel's landscape · Tafasitamab's landscape